BioSpace News Archive

Earnings Call to Discuss Results to be Conducted Tuesday, November 5 at 8:00 am ET

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the appointment of Nicolas M. Barthelemy to its board of directors.

Nearly two years of real-world outcomes data on Abiomed’s (NASDAQ: ABMD) Impella RP heart pump shows that when physicians followed the FDA’s approved protocol for Impella RP use they achieved 72% patient survival and 88% native heart recovery.

LASEROPTEK Co., Ltd., a developer and manufacturer of world-class laser devices for aesthetic and medical dermatology applications, is pleased to announce it has signed a nationwide, multi-year, exclusive distribution agreement with Gale Force Aesthetics, LLC

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2019 conference call on Thursday, October 31, at 4 p.m. CT (5 p.m. ET)

Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) today announced that a clinical update on one of the Company’s lead products, naxitamab for the treatment of neuroblastoma and osteosarcoma, was made at the International Society of Pediatric Oncology (SIOP) Annual Congress held in Lyon, France

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the Company”) today announced a poster presentation at the IgNS 2019 National Conference in Las Vegas that evaluates the performance of the Company’s HIgH-Flo Super26™ Subcutaneous Safety Needle Set (HIgH-Flo Super26™) against that of the Company’s standard HIgH-Flo™ 26G Needle Set in areas including patient infusion time, tolerability, comfort, and overall satisfaction.

Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the Galien Foundation has awarded the prestigious 2019 Prix Galien USA Award for Best Biotechnology Product to LUXTURNA® (voretigene neparvovec-rzyl).